By Steven Kingsley
What is the Best Penis Extender? Extenders Explained.
So what are penis extenders?
Penis extenders are medical therapy devices, usually worn for about 6-8 hours per day, with the goal of increasing penis length permanently
A penis extender is a compact device, lightweight, and provides constant stretching force. It is worn when the penis is in the flaccid state.
Depending on the model and the maker, a penis extender can be adjustable to accommodate different penis sizes and adjust the force applied to the penis.
Check out best penis extenders before you buy one.
How to Buy the Best Penis Extender Properly?
There are a few pitfalls you must not fall into.
For example: Do not fall for a product that is cheap as it may bring undesirable results. Choose a product from a reputable brand even if it costs high.
Through this way, you can ensure that the product has passed safety standards – you have support in case the product in case it craps out.
Basically, the best penis extender is the one with padding around the two rods and the rings to keep the penis head from getting irritated.
Also, the rod locks must be sturdy enough to hold the penis. You need to choose the brand with good reputation and not the brand that is unknown to you.
There different models and brands available (PhalloGauge, SizeGenetics, X4Labs), and it can be very confusing which product is the best.
When you go out and try to find the best penis extender, you will find your options overwhelming.
So make sure you read up on all the sales information.
A Surefire-Way to Get Results Quickly
Everybody wants quick results – I know I wanted them too.
But you must start off slow.
This helps you get acclimated to the enlargement process. Don’t be tempted to increase the tension as you might experience pain or discomfort and have to start over after a one or two day rest.
For the first week, extend your penis too a length not greater than your erect length.
This is the surefire way.
Important disclaimer: For detailed instructions, please refer the user manual that came with your extender.
How to Choose the Best Penis Extender
Picking the right one is very important.
That article is by Dr. Jeff Ferrara, a medical doctor who specializes in medical devices.
After adjusting the unit to the proper length, you might have to back off on the thumb-screws in order to get it on. Once on, readjust to the original setting.
Add or remove length by using a combination of the screws and rod segments if possible (this depends on the type of extender).
For pulling extenders – adjust the tension in the belt.
Now, with the extender off, adjust it to your erection measurement; taking into account any amount of your penis head that might extend past the end of the extender.
Measure the length of your erection from the pubic bone to the tip of the penis (BPEL).
The technical aspect of how the best penis extenders operate.
The traction allows the cells in the muscles of the penis to deplete, and makes the sexual organ to become larger and firmer.
The standard best penis extender has two rings – one that fits the head of the penis and one ring that fits on the penis base.
The head ring holds the penis in place while being stretched. The two rings are connected by the two long rods, and allow the medical device to be adjusted according to the length of the penis.
Slippage is a common problem. How to Avoid It.
Then use your preferred strap to attach it. The wrapped material should be snug and not too tight.
This technique usually helps prevent the strap or noose from slipping past head of your penis.
Hopefully you bought an extender that gives you other options for attachment like a silicone noose or Velcro strap.
Believe it or not, the noose can be very effective and comfortable when used with proper padding or other pieces of protection.
Don’t worry if your penis slips out from the rubber strap – this typically only happens on only the best penis extenders, as this is a common problem.
Over tightening will not help and will create other problems. To avoid slippage, follow the tips and tricks below.
Try a foam pad, gauze, baby wipe, or similar material wrapped around your penis just behind the head.
By: Steven Kingsley
Most guys want an answer for how to last longer in bed. In one recent survey, roughly 75% of all men polled agreed that they could benefit from knowing how to last longer in bed for men.
his high of a number helps to shed some light on the fact that a lot of men experience premature ejaculation, but most men are apt to ever admit that they wouldn’t mind having a few extra last longer tips handy when they are doing the deed with their significant other.
There is a wide variety of different methods that one can consider using when trying to stave off premature ejaculation.
The truth told, one can never truly have enough of these tricks up their sleeve, as premature ejaculation tends to be fleeting; one night if does not affect you, but the next night you struggle to last longer.
Take some simply mental notes on the following tips; they may just turn out to be your sexual savor the next time you go for a toss in the sack and want to perform for longer.
These are the methods Learn when to stop having sex.
The best tip that can be offered for how to last longer in bed for men is in knowing when to stop having sex. This means that you have to identify your points of climax.
Breathe in and out through your nose. This will control your levels of arousal and sexual excitement.
Start using condoms.
Even if you are in a committed relationship; they will help you last
Pleasure your lover at all times. Use external clitoral stimulation, and try extending foreplay to bring your lover closer to climax before penetration. Use circular thrusting methods. This will help to reduce pressure on the tip of the penis during sex.
Use more positions.
Don’t just stick to one or two, but try five or ten. This will give you a few seconds break to cool down in between positions.
Divert your mind to avoid early climax. If you feel yourself getting near, try to distract your mind to avoid premature ejaculation. One solid method is to focus on the tip of your tongue as you press it against the roof of your mouth.
Masturbate before you have sex
This will enable you to easily know how the last longer in bed for men.
Retain control of the situation. Don’t let your sexual excitement overwhelm you. Use your pelvic muscles. The pelvic muscles can help control orgasm. Squeeze your rectum tightly as you thrust in, and release it as you pull out. This will help control circulation and delay orgasm.
Sexual aids could be anything from DVDs, sex toys, slow romantic music, etc. It will take you a while, but try to find that thing that makes you both stimulated for the next round of pleasure while recuperating from an orgasm.
To add the cherry on the cake, applying natural male enhancements will make you last far longer in bed while giving your partner indescribable pleasure.
By Steven Kingsley
Detected in its early stages, prostate cancer can be effectively treated and cured. In men, prostate cancer develops very slowly; most men will never realize they have the condition. Prostate cancer is a malignant tumor of the prostate gland.
One symptom is difficulty starting urination or holding back urine. One symptom is a need to urinate frequently, especially at night. Blood in the urine or semen and frequent pain or stiffness in the lower back, hips, or upper thighs are often symptoms of cancer.
Most symptoms, although associated with prostate cancer, are more likely to be connected to non-cancerous conditions. Because symptoms can mimic other diseases or disorders, men who experience any of these symptoms should undergo a thorough work-up to determine the underlying cause of the symptoms. Having one or more cancer symptoms does not necessarily mean that you have the prostate cancer.
One downside to PSA testing is that health care providers are detecting and treating some very early-stage prostate cancers that may never have caused the patient any harm. A number of tests may be done to confirm a diagnosis. A PSA test with a high level can also be from a non-cancerous enlargement of the prostate gland.
Men’s Health has a pretty good explanation of this test.
A urinalysis may indicate if there is blood in the urine. Another test usually used when prostate cancer symptoms are present is the digital rectal exam (DRE) performed by the doctor. A chest x-ray may be done to see if there’s a spread of cancer.
The conventional treatment of prostate cancer is often controversial. Surgery, radiation therapy, and hormonal therapy can interfere with libido on a temporary or permanent basis. Medications can have many side effects, including hot flashes and loss of sexual desire.
Be aware that some men choose natural treatment options and forgo any surgery, radiation or chemotherapy. Anyone considering surgery should be aware of the benefits, risks and the extent of the procedure. In patients whose health makes the risk of surgery unacceptably high, radiation therapy is often the chosen conventional alternative.
Surgery, called a radical prostatectomy, removes the entire prostate gland and some of the surrounding tissues. Surgery is usually only recommended after thorough evaluation and discussion of all available treatment options. Other medications used for hormonal therapy, with side effects, include androgen-blocking agents, which prevent testosterone from attaching to prostate cells.
Chemotherapy medications are often used to treat prostate cancers that are resistant to hormonal treatments. Whether radiation is as good as removing the prostate is debatable and the decision about which to choose, if any, can be difficult. Treatment options can vary based on the stage of the tumor.
If chemotherapy is decided upon after the first round of chemotherapy, most men receive further doses on an outpatient basis at a clinic or physician’s office. Besides hormonal drugs, hormone manipulation may also be done by surgically removing the testes.
If you haven’t been diagnosed but are concerned about symptoms you should call for an appointment to see your doctor; and if you’re a man older than 50 who has never been screened for prostate cancer (by rectal exam and/or PSA level determination) or not had a regular annual exam, or have had a family history of prostate cancer, make an appointment soon. It’s important to get as informed as possible and read all the newest books, ebooks and research available. Consider sites, such as this one, just a starting point where you can begin to learn about prostate cancer.
By Steven Kingsley
Why Does Jelqing Work? What’s the Science Behind It?
Jelqing works because of the penile tissue cell expansion principle.
The best advice for any man thinking about jelqing is to give it a try, keep the end goal in sight, and persist with it.
This is not an overnight answer to a guy’s common quest to be bigger and better when it comes to sexual prowess.
Jelqing works by increasing the level of blood flow to the penis.
As the penis expands, eventual growth will take place. Jelqing results will vary according to the person, how often the exercise is performed, variations in the exercise, use of other supplements, and a man’s level of tolerance.
However, when performed properly, it is a safe technique that can make the entire sexual experience more enjoyable after persistent use of jelqing exercises.
So go here if you want to learn in detail how to jelq, otherwise we’ll cover it more in detail now.
The Crash-Course Notes of Jelqing
Before starting in on a daily jelqing regimen, it’s essential to know the basics.
Improperly exercising can result in injury and put a person out of order, the last thing any man wants to hear.
Only go semi-erect especially when first starting out.
Men who have become experts in this technique may feel comfortable and satisfied with jelqing on a fully erect penis, but this is recommended for the highly skilled person.
If at any point, too much strain or pain is felt on the penis, it’s time to listen to what the body is saying and stop before any jelqing damage is done.
What Type of Men Would Benefit from Jelqing?
Pretty much all men starting a penis enlargement regimen.
Or if you haven’t done any penis enhancement for 18 months.
Newbies that haven’t done any form of penis enhancement consistently.
What Can I Expect From This Routine?
Big results from jelqs.
No but seriously:
With consistency and commitment, you can reasonably expect to gain 1.5 to 2 inches in length from jelqing and .5 to 1.8 inches in girth in a period of 7 to 15 months.
They get harder to make and require more advanced routines in the future. You can probably stick with this one for 8 to 12 weeks.
The jelqing gains come quick if you are just starting out.
Gaining .5-1 inch in length and .5-.75 inches in girth during the first 4-8 weeks is very possible.*
Prevent Stretching Your Skin While Jelqing
Skin stretching is generally undesirable because you want your penis to grow evenly – shaft and all.
Others want to focus more on the penis shaft alone. Some skin pull is actually considered good because it helps adding “thickness” to your penis.
To prevent jelqing skin pulling:
- Consider using a softer grip
- Definitely use lubricant (water-based is best).
- Increase blood flow to the penis (harder erection).
- Use your “off-hand” to hold the base of your penis skin back.
A Solid Routine for All Men to Follow:
You should jelq 4 or 5 times per week. It is nice to take a day’s break from time to time to allow the muscles and blood vessels to recover.
That’s how you do jelqing.
10 minutes per session on average is ideal.
Throughout your jelqing session, stroke your penis continuously without stopping. If your hand gets tired or your penis gets sore, take a break for a minute, then continue.
If you’re going for more than 20 minutes – you’re doing jelqing wrong!
Do jelqing for at least for a few minutes to massage your penis and redistribute the blood evenly.
If you are using a pump or an extender, always jelq when you finish using the device.
At that time, jelqing will be more effective and more enjoyable.
During your shower, or immediately after you get out, your penis muscles will be more relaxed.
Not to mention jelqing feels great too.
Some Notes to Understand Before Jelqing
Super hard jelqing simply does not work.
It does not work if you study jelqing. I have spoken with others and the results are the same.
I do jelqing every single day. Go big or go home as I always say. Every guy should be jelqing every single day of their life in order to truly benefit.
Tough, but that’s the truth.
What I have learned is split or on and off days routines work best. You need rest days. It makes sense to jelq and rest. Or use very light daily schedules.
Do a ten minute jelqing routine (tell that to an erect jelqer – lmao – they need an hour routine to combat the dick shrink) and see where your measurements go.
I’m using a a light 5 day a week 10 minute jelq routine and I have gained over an inch in length and .75 in width in just one month
of correct jelqing.
Be very careful with those touting erect jelqing as some advanced technique – it is for advanced idiots.
So remember! Don’t be fooled by crappy jelqing information!
You have to form good habits when you’re first starting jelqing.
We highly suggest going as far as timing each rep using a stopwatch.
This will allow you to commit the full 5 seconds to muscle memory.
Have you tried jelqing?
If you are interested in trying jelqing, we would like to emphasize that a “large” penis is not necessary for a satisfying sex life.
Your body is a beautiful, wonderful thing just how it is. Meaningful partners will care more about YOU than the size of your body parts.
What do you think about this penis exercise?
Has it actually improved your sexual relationships with women? Has it decreased your anxiety during sex?
Let the experts (like me) tell you how to do it properly!
Archemix technology is based on the in vitro selection of nucleic acids. In the same way combinatorial chemistry produces millions of compounds that feed the drug discovery pipeline, in vitro selection of nucleic acids yields compounds (nucleic acids) with useful biological activities. Through this process, enormous libraries (up to 1016 unique compounds) are screened to identify individual compounds best suited to a particular application. This method allows Archemix to generate powerful new compounds, Aptamers and RiboReporters™, that meet specific commercial needs.
Aptamers can be thought of as the nucleic acid antibodies. Archemix’s primary focus is to develop aptamers as a novel source of therapeutics for the treatment of acute and chronic diseases. Like antibodies, aptamers may be also be employed to address critical bottlenecks in the drug discovery process, including target validation and drug screening.
RiboReporters™ are unique sensors in that they are able to directly convert molecular recognition into a detectible signal. Archemix is pursuing the use of RiboReporter™ Sensors in a range of applications.
Aptamers are oligonucleotides that bind to molecular targets in a manner conceptually similar to antibodies. Through the SELEX process, aptamers have been identified against numerous target types including growth factors, enzymes, immunoglobulins, receptors, viral proteins and others. The Archemix preclinical portfolio includes aptamers directed to a wide range of validated therapeutic targets (see Examples). Aptamers are similar to therapeutic antibodies, and as such, have a number of desirable characteristics for use as therapeutics, including biological efficacy, high specificity and affinity, and excellent pharmacokinetic properties. In addition, they offer specific competitive advantages such as:
- aptamers are produced by an entirely in vitro process, which allows for the generation of initial therapeutic leads in as little as two weeks. In vitro selection allows the specificity and affinity of the aptamer to be tightly controlled, including selection against both toxic and non-immunogenic targets.
- aptamers are able to disrupt protein-protein interactions
- aptamers as a class have demonstrated little or no immunogenicity or toxicity.
- aptamer therapeutics can be administered subcutaneously.
- aptamers are chemically synthesized, allowing for lower cost and easily scaled production.
- aptamers can be stored at room temperature as lyophilized powders.
Archemix and Nuvelo Close Phase I Trial for Thrombin Inhibitor, ARC183 – With “Proof of Concept” Achieved, Companies Actively Pursuing an Optimized Second Generation Molecule
By Steven Kingsley
CAMBRIDGE, Mass. and SUNNYVALE, Calif., September 21, 2005 – Archemix Corp. and Nuvelo, Inc. (Nasdaq: NUVO) today announced that they have closed a Phase 1 clinical trial evaluating ARC183 as an anticoagulant for potential use in acute cardiovascular settings such as coronary artery bypass graft (CABG) surgery. Preliminary results from the trial show that administration of ARC183 resulted in a rapid onset of anticoagulation, demonstrated stable, dose-related anticoagulation activity and that the effects of the drug rapidly reversed after administration of the drug infusion ceased. However, the amount of drug needed to achieve the desired anticoagulation for use in CABG surgery resulted in a sub-optimal dosing profile. For that reason, the companies have decided not to pursue development of ARC183, and instead are actively pursuing an optimized second generation molecule.
“This study validated the ability of ARC183 to achieve a rapid onset and offset of anticoagulation,” said Claude Benedict, M.D., Ph.D., head of clinical development at Archemix. “With these insights in hand, we feel we have a solid proof of concept that we are now applying to the development of a more potent second generation molecule.”
The Phase 1 study was an open-label dose-escalation trial designed to evaluate the safety, tolerability, anticoagulation activity and titratability of ARC183 in two cohorts. Dosing has completed in the first cohort, which included 40 healthy volunteers. The second cohort, which was to include 16 patients with coronary artery disease, was closed prior to dosing in all patients due to the decision by both companies to pursue a second generation molecule that could offer superior potency and efficacy than what was being observed with ARC183.
“There is a clear need for an anticoagulant with fewer side effects and more predictable dosing than heparin. Heparin, followed by protamine reversal, has significant limitations such as bleeding, heparin-induced thrombocytopenia (HIT), erratic anticoagulant effect and hypotension,” said Steven R. Deitcher, M.D., vice president of medical affairs for Nuvelo. “We are encouraged by the preliminary data from this trial and are optimistic that we will identify a more potent product candidate that meets the high standards that Archemix and Nuvelo have set.”
About the Collaboration
In January 2004, a worldwide collaboration agreement was formed between Archemix and Nuvelo for the development and commercialization of anti-thrombin aptamers. Under the terms of the agreement, Archemix will initially lead development and be responsible for all clinical development activities. Nuvelo will have the option to lead commercialization efforts in which both companies may participate. As part of the transaction, Archemix and Nuvelo will equally share all costs associated with the development and marketing of anti-thrombin aptamers and will have 50/50 ownership of the compound.
Archemix Corp. is a privately-held biopharmaceutical company based in Cambridge, Massachusetts. The company’s mission is to develop aptamers as a class of directed therapeutics for the treatment of human disease. Aptamers are single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind target molecules in a manner conceptually similar to antibodies. Aptamers combine the optimal characteristics of small molecules and antibodies, including high specificity and affinity, chemical and biological stability and immunogenicity and the ability to target protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically synthesized rather than biologically expressed, offering a significant cost advantage. Because of their unique properties and proven efficacy, aptamers are a superior alternative to biologics and small molecules and will be a major class of drugs for the treatment of unmet medical needs.
Archemix’s aptamer expertise is complemented by a dominant patent estate comprised of over 220 issued and 230 pending patents covering the identification, composition and use of therapeutic aptamers. In addition to the company’s core aptamer generation technology, Archemix possesses strong expertise in both preclinical and clinical drug development. Further information about Archemix can be found at http://www.archemix.com.
For further information or to speak with Dr. Errol De Souza, president and chief executive officer, please contact Davia Temin of Temin and Company at 212-588-8788 or email@example.com.
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s clinical pipeline includes alfimeprase, a direct acting thrombolytic in Phase 3 trials for the treatment of acute peripheral arterial occlusion (PAO) and catheter occlusion and rNAPc2, an anticoagulant currently in Phase 2 trials that inhibits the factor VIIa and tissue factor complex. Nuvelo recently identified NU206 as a preclinical development candidate from its proprietary research programs and expects to leverage expertise in secreted proteins and antibody discovery to expand its pipeline and create partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 408-215-4000.
This press release contains “forward-looking statements” regarding the progress and potential therapeutic benefits of Archemix’s and Nuvelo’s collaborative research and development programs. These statements are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes; uncertainties relating to patent protection and uncertainties relating to our ability to obtain funding. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo’s recent annual report on Form 10-K for the year ended December 31, 2004 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.
Aptamer Therapeutics: A New Frontier in Drug Development
Article by Steven Kingsley
Archemix is the biopharmaceutical company leading the development of aptamers as a new class of directed therapeutics for the prevention and treatment of chronic and acute disease.
Archemix believes the unique properties of aptamers hold extraordinary potential in the fast-breaking world of drug discovery and development. Because of their unequaled specificity for their molecular targets, aptamers provide a promising alternative to conventional therapeutic approaches. Aptamers can be used in a wide range of disease areas, including many of those currently addressed by protein-based therapeutics. Aptamers demonstrate little to no immunogenicity or toxicity, and can be produced quickly and economically.
With a portfolio of over 300 patents and patent applications, Archemix holds the key to the development of aptamer technology and its implications for the pharmaceutical industry. We are committed to using our expertise to aggressively pursue drug discovery and development for the benefit of all.
Archemix Announces Milestone Achievement with Candidate Selection
by Eyetech as Part of Broad Collaboration to Discover and Develop Therapeutic Aptamers for Ophthalmology
CAMBRIDGE, Mass., June 22 /PRNewswire/ — Archemix Corp. announced today
that Eyetech Pharmaceuticals, Inc. has formally selected and nominated its
first pre-clinical candidate pursuant to the parties’ collaboration agreement,
which was signed in 2004.
The pre-clinical candidate selected by Eyetech is an aptamer directed
against the target Platelet Derived Growth Factor-B (PDGF-B) for potential use
in neovascular age-related macular degeneration (neovascular AMD). In addition
to uses as a single agent, pre-clinical studies have also demonstrated that
aptamers directed against PDGF-B may provide additional benefit when used in
combination with Macugen(R) (pegaptanib sodium injection) for neovascular AMD.
In conjunction with this milestone, Archemix received an undisclosed payment
“Eyetech is pleased to announce that a candidate has been selected,”
stated Dr. David Guyer, Chief Executive Officer of Eyetech Pharmaceuticals.
“The speed with which we were able to select this candidate is indicative of
the quality of our collaboration and the science behind it. We view this
selection as an important step in building and deepening our product pipeline.
The use of combination therapy may represent the future direction of
ophthalmic treatment, and the opportunity to test an anti-PDGF aptamer with
Macugen places us on the cutting edge of this potential new paradigm of
“For Archemix, this candidate milestone demonstrates the value of our
expertise in therapeutic aptamers and our commitment to this collaboration,”
stated Dr. Errol De Souza, President and Chief Executive Officer of Archemix.
“The selection of a development candidate in less than one year after the
agreement was signed shows that our proprietary selection methods and know-how
translate into rapid discovery of high quality drug candidates. We look
forward to Eyetech using their extensive expertise to develop this and other
candidates that come out of this collaboration.”
Eyetech’s compound Macugen is being marketed with Pfizer Inc for the
treatment of all types of the neovascular AMD, the leading cause of
irreversible vision loss in developed countries in people over 60 years of
age. In addition, Eyetech and Pfizer are conducting a Phase 2 clinical trial
for the use of Macugen for the treatment of diabetic macular edema (DME), a
leading cause of blindness in younger people. Macugen is also being studied
for other indications including retinal vein occlusion.
Aptamers are single-stranded nucleic acids that form well-defined three-dimensional shapes,
binding target molecules in a manner conceptually similar
to antibodies. Aptamers have a number of desirable characteristics for use as
therapeutics, including clinically demonstrated biological efficacy, high
specificity and affinity, and excellent pharmacokinetic properties.
Archemix Corp. is a privately held biopharmaceutical company based in
Cambridge, Massachusetts. The company’s mission is to develop aptamers as a
class of directed therapeutics for the treatment of human disease. Because of
their unique properties and proven efficacy, aptamers are a superior
alternative to biologics and small molecules and will be a major class of
drugs for the treatment of unmet medical needs.
Archemix’s aptamer expertise is complemented by a dominant patent estate
comprised of over 220 issued and 230 pending patents covering the
identification, composition and use of therapeutic aptamers. In addition to
the company’s core aptamer generation technology, Archemix possesses strong
expertise in both pre-clinical and clinical drug development. Further
information about Archemix can be found at http://www.archemix.com.
For further information or to speak with Dr. Errol De Souza, please
contact Davia Temin of Temin and Company at 212-588-8788 or
Boston Scientific Chief Financial Officer, Lawrence C. Best,
Joins Archemix Corp. Board of Directors
CAMBRIDGE, MA April 26, 2005 Archemix Corp., the privately-held
biopharmaceutical company focused on discovering and developing aptamer-based
therapeutics, announced today that Lawrence C. Best has been appointed to the
Companys Board of Directors. In addition to his responsibilities as a
Board member, Mr. Best qualifies as an Audit Committee Financial Expert in
accordance with Regulation S-K 401(h) and the rules implementing Section 407 of
the Sarbanes-Oxley Act.
Mr. Best currently serves as Executive
Vice President and Chief Financial Officer of Boston Scientific Corporation. He
brings more than 30 years of financial experience to Archemix. Prior to
his work with Boston Scientific, Mr. Best was a partner in the accounting firm
of Ernst & Young, where he specialized in serving multinational companies in
the high technology and life sciences fields. He served a two-year fellowship at
the Securities and Exchange Commission from 1979 to 1981 and a one-year term as
a White House-appointed Presidential Exchange Executive in Washington. Mr. Best is also a Director and Audit
Committee Financial Expert for Biogen Idec and Haemonetics Corporation.
privileged to have someone of Larrys experience and knowledge join our Board,
commented Dr. Errol De Souza, Chief Executive Officer of Archemix. “Larry brings
an impressive record of financial expertise and strategic management and has
been a key member of the Boston Scientific executive team that is credited with
building one of the foremost companies in the medical device industry.
Dr. De Souza also stated that filling the role of financial expert is an
important step for Archemix as we continue to evolve our Board to meet the
requirements of a public company.
Archemix is at an exciting stage of its development,
said Mr. Best. The Companys aptamers have the potential to bring forth a new
class of therapeutics for the treatment of acute and chronic diseases. I look
forward to contributing to Archemix as the company strives to meet its strategic
initiatives and develops its portfolio of aptamer therapeutics.
are single-stranded nucleic acids that form well-defined three-dimensional
shapes, allowing them to bind to target molecules in a manner that is
conceptually similar to antibodies. Aptamers combine the optimal characteristics
of small molecules and antibodies, including high specificity and affinity,
chemical and biological stability, low toxicity and immunogenicity and the
ability to target protein-protein interactions. In contrast to monoclonal
antibodies, aptamers are chemically synthesized rather than biologically
expressed, offering a significant cost advantage. As therapeutic agents,
aptamers have demonstrated clinical biological efficacy and have excellent,
tunable pharmacokinetic properties.
Corp. is a privately-held biopharmaceutical company based in
Cambridge, Massachusetts. The company’s
mission is to develop aptamers as a class of directed therapeutics for the
treatment of human disease. Because of their unique properties and proven
efficacy, aptamers are a superior alternative to biologics and small molecules
and will be a major class of drugs for the treatment of unmet medical needs.
Archemix’s aptamer expertise is complemented by a
dominant patent estate comprised of over 220 issued and 230 pending patents
covering the identification, composition and use of therapeutic aptamers. In
addition to the company’s core aptamer generation technology, Archemix possesses
strong expertise in both preclinical and clinical drug development. Further
information about Archemix can be found at
Archemix Names Page
Bouchard Senior Vice President of Preclinical Drug Discovery and Development
CAMBRIDGE, Mass., Nov. 4 /PRNewswire/ — Archemix Corp., the privately-held
biopharmaceutical company discovering and developing aptamer therapeutics,
announced today the appointment of Dr. Page Bouchard as Senior Vice President of
Preclinical Drug Discovery and Development. Dr. Bouchard will have
responsibility for directing the Company’s preclinical pharmacology, drug
metabolism and pharmacokinetics and drug safety efforts.
“Page has extensive experience in the area of preclinical drug discovery and
development and will lead this important multifunctional area at Archemix,” said
Dr. Errol De Souza, President and Chief Executive Officer of Archemix. “Page
possesses the unique combination of scientific experience and leadership skills
necessary to move our rapidly expanding pipeline of therapeutic aptamer leads
into clinical development. We are delighted to have Page as a part of our team
and look forward to his contributions to the development of aptamer therapeutic
products and the generation of shareholder value.”
“Archemix is at an exciting stage of its development,” commented Dr. Bouchard.
“The company’s aptamer technology has the potential to bring forth an entirely
new class of therapeutics for the treatment of acute and chronic diseases. I
look forward to leveraging my experience with both biotherapeutics and small
molecule drug candidates to this new class of therapeutics. The efficient
integration of preclinical and clinical development activities with novel
technology, rigorous science and focused strategic planning will lead to
significant product opportunities.”
Prior to joining Archemix, Dr. Bouchard was Vice President, Drug Safety
Evaluation at Millennium Pharmaceuticals. In this position, Dr. Bouchard led the
preclinical Drug Safety and Pathology organization, leading development projects
to critical clinical and regulatory milestones. Prior to joining Millennium, Dr.
Bouchard was Assistant Vice President of Pathology at Wyeth-Ayerst, heading the
discovery support pathology, toxicologic pathology, clinical pathology and
Dr. Bouchard received a bachelor’s degree from Wesleyan University and a D.V.M.
from Tufts University Veterinary School. He trained in veterinary pathology at
Cornell Veterinary School and is board certified in veterinary pathology by the
American College of Veterinary Pathologists.
Aptamers are single-stranded nucleic acids that form well-defined
three-dimensional shapes, allowing them to bind to target molecules in a manner
that is conceptually similar to antibodies. Aptamers combine the optimal
characteristics of small molecules and antibodies, including high specificity
and affinity, chemical and biological stability, low toxicity and immunogenicity
and the ability to target protein-protein interactions. In contrast to
monoclonal antibodies, aptamers are chemically synthesized rather than
biologically expressed, offering a significant cost advantage. As therapeutic
agents, aptamers have demonstrated clinical biological efficacy and have
excellent, tunable pharmacokinetic properties.
About Archemix Corp.
Archemix Corp. is a privately-held biopharmaceutical company based in Cambridge,
Massachusetts. The company’s mission is to develop aptamers as a class of
directed therapeutics for the treatment of human disease. Because of their
unique properties and proven efficacy, aptamers are a superior alternative to
biologics and small molecules and will be a major class of drugs for the
treatment of unmet medical needs.
Archemix’s aptamer expertise is complemented by a dominant patent estate
comprised of over 180 issued and 220 pending patents covering the
identification, composition and use of therapeutic aptamers. In addition to the
company’s core aptamer generation technology, Archemix possesses strong
expertise in both preclinical and clinical drug development. Further information
about Archemix can be found at http://www.archemix.com/.
For further information or to speak with Dr. Errol De Souza or Dr. Page
Bouchard, please contact Davia Temin of Temin and Company at (212) 588-8788 or